Jazz Pharmaceuticals Announces First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Jazz Pharmaceuticals (JAZZ) Tops Q1 EPS by 21c
May 4, 2021 4:51 PM EDTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $3.92, $0.21 better than the analyst estimate of $3.71. Revenue for the quarter came in at $607.58 million versus the consensus estimate of $608.24 million.
"Demand for Xywav is strong, as both patients and physicians embrace the health benefits associated with reducing daily sodium intake. We also continue to see robust uptake of Zepzelca among both platinum-resistant and platinum-sensitive small cell lung cancer patients,... More
